March 23, 2021
A California federal judge on Tuesday rejected Eli Lilly & Co.'s bid for $10 million in attorney fees alleging Genentech Inc. dragged out litigation before dropping its patent suit over a psoriasis drug while noting Genentech unreasonably failed to tell the USPTO about a Federal Circuit decision weakening its claim to patent protection.
May 01, 2020
Genentech has told a California federal court that it acted in good faith when it accused Eli Lilly of infringing its patent through the sale of a psoriasis drug and therefore should not have to cover the $10 million Eli Lilly says it spent fending off the suit.
April 02, 2020
Genentech knew it had no case when it accused Eli Lilly in California federal court of infringing its patent through the sale of a psoriasis drug, the latter said Wednesday in a bid to get Genentech to cover the $10 million it spent on attorney fees while fending off the suit.
July 05, 2018
Genentech has sued Eli Lilly for infringing the asserted claims of a just-issued patent through sales of Taltz, a psoriasis drug that has been on the market since 2016, according to a complaint filed in the Southern District of California.